UA88643C2 - Производные амида гетероциклической карбоновой кислоты - Google Patents

Производные амида гетероциклической карбоновой кислоты

Info

Publication number
UA88643C2
UA88643C2 UAA200702172A UAA200702172A UA88643C2 UA 88643 C2 UA88643 C2 UA 88643C2 UA A200702172 A UAA200702172 A UA A200702172A UA A200702172 A UAA200702172 A UA A200702172A UA 88643 C2 UA88643 C2 UA 88643C2
Authority
UA
Ukraine
Prior art keywords
carboxylic acid
acid amide
amide derivatives
halogen atom
heterocyclic carboxylic
Prior art date
Application number
UAA200702172A
Other languages
English (en)
Ukrainian (uk)
Inventor
Иштван Борза
Чилла Хорват
Шандор Фаркаш
Иштван Дьертьян
Йожеф Надь
Шандор Колок
Корнель Галгоци
Каталин Шаги
Original Assignee
Рихтер Гедеон Ведьесети Дьяр Рт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рихтер Гедеон Ведьесети Дьяр Рт. filed Critical Рихтер Гедеон Ведьесети Дьяр Рт.
Publication of UA88643C2 publication Critical patent/UA88643C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)

Abstract

Даное изобретение касается новых производных амида гетероциклической карбоновой кислоты формулы (І), в которой значение X соответствует водороду или атому галогена, гидрокси, циано, С-Салкилсульфонамидо необязательно замещенной атомом галогена или атомами галогена, С-Салканоиламидо, необязательно замещенной атомом галогена или атомами галогена, арилсульфонамидогруппам, Y соответствует -СН= группе или атому -N=, Z соответствует одному или более атомам водорода или атомам галогена, С-Салкильной, С-Салкокси, циано, трифторметильной, трифторметоксигруппе, а также их солей, которые являются антагонистами NMDA рецептора или представляют собой промежуточные продукты для их получения.(I)
UAA200702172A 2004-07-29 2005-07-21 Производные амида гетероциклической карбоновой кислоты UA88643C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0401527A HU227119B1 (en) 2004-07-29 2004-07-29 Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
UA88643C2 true UA88643C2 (ru) 2009-11-10

Family

ID=89985412

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200702172A UA88643C2 (ru) 2004-07-29 2005-07-21 Производные амида гетероциклической карбоновой кислоты

Country Status (20)

Country Link
US (1) US20080300276A1 (ru)
EP (1) EP1771437A1 (ru)
JP (1) JP2008508251A (ru)
KR (1) KR20070038503A (ru)
CN (1) CN1989126A (ru)
AP (1) AP2076A (ru)
AU (1) AU2005266164A1 (ru)
BR (1) BRPI0513900A (ru)
CA (1) CA2574169A1 (ru)
EA (1) EA011635B1 (ru)
GE (1) GEP20084494B (ru)
HU (1) HU227119B1 (ru)
IL (1) IL179483A0 (ru)
MA (1) MA28818B1 (ru)
MX (1) MX2007001049A (ru)
NO (1) NO20071112L (ru)
TN (1) TNSN07014A1 (ru)
UA (1) UA88643C2 (ru)
WO (1) WO2006010969A1 (ru)
ZA (1) ZA200700329B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007099828A1 (ja) 2006-02-23 2009-07-16 塩野義製薬株式会社 環式基で置換された含窒素複素環誘導体
MX2012008721A (es) 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
MA53944A (fr) 2014-08-28 2021-08-25 Asceneuron Sa Inhibiteurs de la glycosidase
WO2017106254A1 (en) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
AU2017222962B2 (en) 2016-02-25 2021-03-25 Asceneuron S. A. Acid addition salts of piperazine derivatives
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CN1989126A (zh) 2007-06-27
ZA200700329B (en) 2008-05-28
HU0401527D0 (en) 2004-09-28
MA28818B1 (fr) 2007-08-01
KR20070038503A (ko) 2007-04-10
AU2005266164A1 (en) 2006-02-02
HUP0401527A3 (en) 2008-04-28
TNSN07014A1 (en) 2008-06-02
JP2008508251A (ja) 2008-03-21
BRPI0513900A (pt) 2008-05-20
EA200700360A1 (ru) 2007-06-29
IL179483A0 (en) 2007-05-15
MX2007001049A (es) 2007-04-16
WO2006010969A8 (en) 2006-08-31
HUP0401527A2 (en) 2006-01-30
US20080300276A1 (en) 2008-12-04
EA011635B1 (ru) 2009-04-28
AP2006003843A0 (en) 2006-12-31
EP1771437A1 (en) 2007-04-11
GEP20084494B (en) 2008-09-25
CA2574169A1 (en) 2006-02-02
AP2076A (en) 2009-12-17
NO20071112L (no) 2007-02-27
WO2006010969A1 (en) 2006-02-02
HU227119B1 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
UA88643C2 (ru) Производные амида гетероциклической карбоновой кислоты
MY136959A (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
CY1107221T1 (el) Παραγωγα τριαζολιου ως ανταγωνιστες υποδοχεα ταχυκινινης
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
WO2005103039A8 (en) 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
TWI370121B (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
NO2012021I1 (no) Perampanel eller salter eller hydrater derav
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
WO2008105386A1 (ja) アルコキシ基を有するレキシノイド化合物
MX2009010790A (es) Derivados de heteroarilo biciclico fusionados.
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
IL180312A0 (en) Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 recepor antagonists
MX338631B (es) 5-(fenil/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores del receptor de glutamato metabotropico del subtipo 5 (mglur5).
UA102101C2 (ru) Агонист глюкокортикоидного рецептора, который содержит 2,2,4-триметил-6-фенил-1,2-дигидрохинолиновые производные, которые имеют замещенную оксигруппу
EA201270421A1 (ru) 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт
EA200700364A1 (ru) Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda
NO20061831L (no) Benzofuranderivater av karbamoyltype
WO2008037681A8 (en) 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl] ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc.
TN2011000620A1 (en) Novel fumarate salts of a histamine h3 receptor antagonist
UA110343C2 (en) Spiro heterocyclic compounds as antagonists mglur5
MX2010007929A (es) Imidazolinilmetil aril sulfonamidas novedosas.